Objective: Critical limb ischemia remains a difficult disease to treat, with limited level 1 data. The Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial is attempting to answer whether initial treatment with surgical bypass or endovascular therapy improves outcomes. Although still in the enrollment phase, this study aims to compare amputation-free survival (AFS) and reintervention in patients treated with initial open surgical bypass or endovascular intervention for ischemic ulcers of the lower extremities.
Objective: Critical limb ischemia remains a difficult disease to treat, with limited level 1 data. The Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial is attempting to answer whether initial treatment with surgical bypass or endovascular therapy improves outcomes. Although still in the enrollment phase, this study aims to compare amputation-free survival (AFS) and reintervention in patients treated with initial open surgical bypass or endovascular intervention for ischemic ulcers of the lower extremities.
Methods: By use of statewide data, all patients were identified with lower extremity ulcers and a diagnosis of peripheral arterial disease who underwent a revascularization procedure from 2005 to 2013. Propensity scores were formulated from baseline characteristics of the patients. Inverse probability weighting was used within Kaplan-Meier analysis to determine AFS and time to reintervention for open vs endovascular treatment. Cox proportional hazards modeling was used to adjust for access to care and hospital revascularization experience.
Results: A total of 16,800 patients were identified. Open surgical bypass was the initial treatment of 5970 (36%) patients, whereas 10,830 (64%) underwent endovascular interventions. Patients in the endovascular group were slightly younger compared with the open group (70 vs 72 years; standard deviation, 12 years; P < .001). Endovascular patients were more likely to have renal failure (36% vs 24%) and coronary artery disease (34% vs 32%), whereas patients in the open bypass group were more likely to have diabetes mellitus (30% vs 44%; all P values < .05). After propensity weighting, open first treatment was associated with lower rates of reintervention (hazard ratio [HR] Objective: Drug-eluting stents (DESs) are highly efficacious for interventions on coronary saphenous vein graft bypasses, with improved patency over angioplasty and bare-metal stenting. We have used these stents in failing lower extremity bypass grafts with aggressive or refractory stenotic lesions and present the experience at a single institution.
Methods: All patients who underwent DES (coronary stent) placement in an infrainguinal vein bypass graft from 2012 to 2017 were identified through operative records. Demographic, treatment, and follow-up data were extracted retrospectively from the medical record. Wilcoxon signed rank and rank sum tests were used to compare the reintervention-free intervals for paired and unpaired data, respectively.
Results: A total of 22 DESs were placed in 18 lower extremities. Median age at the time of bypass was 64 years (range, 49-84 years). All patients required an infrageniculate distal anastomosis, and great saphenous vein was used. After bypass, patients underwent a mean of 3.3 6 2.4 interventions. Fortyfive percent of reinterventions were for recurrent ischemic symptoms (n ¼ 27); 55% were reintervened on for asymptomatic but concerning surveillance duplex ultrasound findings. Reinterventions included plain balloon angioplasty (percutaneous transluminal angioplasty [PTA] , n ¼ 27), drugcoated balloon angioplasty (n ¼ 6), cutting balloon angioplasty (n ¼ 5), bare-metal stenting (n ¼ 8), and DES placement. DESs were placed for initial (n ¼ 13) or recurrent (n ¼ 9) stenoses. Half of all DESs were placed immediately after PTA that had yielded unsatisfactory residual stenosis on completion angiography. All attempted DES placements were technically successful and required no additional interventions at time of placement. The median time to reintervention or time to last available duplex ultrasound examination demonstrating patency (if no additional reintervention occurred) trended in favor of DES (7.7 months; interquartile range [IQR], 3.7-13.8 months) over standard endovascular interventions (4.8 months; 
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